Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice:

W. M. Brückl,Martin Reck,Frank Griesinger,Harald Schäfer,Cornelius Kortsik,Tobias Gaska,Justyna Rawluk,Stefan Krüger,Konrad Kokowski,Stephan Budweiser,Joachim H. Ficker,Christopher M. Hoffmann,Andrea Schuler,Eckart Laack

Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice:

2021

W. M. Brückl
Martin Reck
Frank Griesinger
Harald Schäfer
Cornelius Kortsik
Tobias Gaska
Justyna Rawluk
Stefan Krüger
Konrad Kokowski
Stephan Budweiser
Joachim H. Ficker
Christopher M. Hoffmann
Andrea Schuler
Eckart Laack

Background:Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10%...

Keywords:

egfr mutation
non small cell
Internal medicine
Afatinib
Oncology
Lung cancer
first line treatment
routine clinical practice
in patient
first line
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations